Insight and IdeasOverviewFree updatesQuick start fundsii Super 60Model PortfoliosWinter Portfolios2021 outlookQuarterly reviewShare tips and ideasAIM and small-cap hubInsider videosii PodcastsHistorical recommendationsMeet the expertsHome>AIM and small-cap hub>AIM and small-cap hub Get the lowdown on smaller company shares and all that matters on the junior market. 26 FebruaryThe performance of new AIM listings – if investors can access themIn the past three years, new AIM admissions have had a 12% first-day premium.by Andrew Hore24 FebruaryWhy Novacyt is back in favour and AIM’s other big movers Investors react as the Covid testing firm continues to adapt to life after a vaccine.by Graeme Evans24 FebruaryStockopedia: how to find companies with the strongest ‘moats’Warren Buffett’s idea of spotting firms with a durable competitive edge still holds water.by Ben Hobson19 FebruaryRichard Beddard: scoring a music stock with Beatles connectionsBeing For The Benefit of Focusrite - plus a reader question on Dewhurst.by Richard Beddard19 FebruaryStockwatch: a good IT share for patient buyersRedcentric is at a watershed moment, but could be about to prosper.by Edmond Jackson18 FebruaryA second look at Genedrive, a stock with room for movement?The share price has had a confused few months, but it could thrive in testing times.by Alistair StrangRegister to receive free daily market commentary, insight and analysis from our award-winning editorial team.
26 FebruaryThe performance of new AIM listings – if investors can access themIn the past three years, new AIM admissions have had a 12% first-day premium.by Andrew Hore
24 FebruaryWhy Novacyt is back in favour and AIM’s other big movers Investors react as the Covid testing firm continues to adapt to life after a vaccine.by Graeme Evans
24 FebruaryStockopedia: how to find companies with the strongest ‘moats’Warren Buffett’s idea of spotting firms with a durable competitive edge still holds water.by Ben Hobson
19 FebruaryRichard Beddard: scoring a music stock with Beatles connectionsBeing For The Benefit of Focusrite - plus a reader question on Dewhurst.by Richard Beddard
19 FebruaryStockwatch: a good IT share for patient buyersRedcentric is at a watershed moment, but could be about to prosper.by Edmond Jackson
18 FebruaryA second look at Genedrive, a stock with room for movement?The share price has had a confused few months, but it could thrive in testing times.by Alistair Strang